@article{RECOVERY_Collaborative_Group-2025_211461,
title = {Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial},
author = {RECOVERY Collaborative Group},
month = {aug},
year = {2025},
abstract = {BACKGROUND: Sotrovimab is a neutralising monoclonal antibody targeting the SARS-CoV-2 spike protein. We aimed to evaluate the efficacy and safety of sotrovimab in the RECOVERY trial, an investigator-initiated, individually randomised, controlled, open-label, adaptive platform trial testing treatments for patients admitted to hospital with COVID-19.},
journal = {The Lancet Infectious Diseases},
publisher = {Elsevier},
url = {https://doi.org/10.1016/S1473-3099(25)00361-5},
}
